<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710888</url>
  </required_header>
  <id_info>
    <org_study_id>3</org_study_id>
    <nct_id>NCT04710888</nct_id>
  </id_info>
  <brief_title>Basil Extract (Ocimum Basilicum) in the Management of Recurrent Aphthous Stomatitis</brief_title>
  <acronym>RCT</acronym>
  <official_title>Muco-bioadhesive Gel Containing Basil Extract (Ocimum Basilicum) in the Management of Recurrent Aphthous Stomatitis: A Randomized Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized double-blind placebo controlled trial will be carried out on 20 patients&#xD;
      complaining from aphthus ulcer and 10 patient healthy control 10 patients treated with&#xD;
      mucoadhesive gel containing 2% of basil extract 4 times per day (test group) for 20 min after&#xD;
      every meal and before going to bed. The other 10 patients treated by mucoadhesive gel without&#xD;
      drug which was used as placebo (composed from 6% w/w PVA (Mw = 31-50 kDa, 98-99% hydrolysed)&#xD;
      and 2% w/w sodium tetraydroxy borate) 4 times per day 10 healthy patients will be selected to&#xD;
      participate in the study to test the salivary level of endocan in the healthy individuals&#xD;
      (negative control group)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized double-blind placebo controlled trial will be carried out on 20 patients&#xD;
      complaining from aphthus ulcer and 10 patient healthy control. Inclusion criteria will be:&#xD;
      (i) age &gt; 18 years; (ii) a clear history of RAS(recurrent apthous stomatitis)occurring no&#xD;
      less than four times a year; (iii) presentation with one or two ulcers measuring 10 mm in&#xD;
      diameter for 48 hours and yet to receive treatment; (iv) ulcers that took &gt; 5 days to resolve&#xD;
      without treatment. Individuals will excluded if they: (i) had underlying systemic disease(s)&#xD;
      or a history of immunologic disorder(s); (ii) were taking immunomodulatory agents or systemic&#xD;
      nonsteroidal anti-inflammatory drugs &lt; 1 month before study commencement; (iii) are smokers;&#xD;
      (iv) are pregnant; (v) had a history of abusing drugs or alcohol; (vi) could not provide&#xD;
      written informed consent.&#xD;
&#xD;
      10 patients treated with mucoadhesive gel containing 2% of basil extract 4 times per day&#xD;
      (test group) for 20 min after every meal and before going to bed. The other 10 patients&#xD;
      treated by mucoadhesive gel without drug which was used as placebo (composed from 6% w/w PVA&#xD;
      (Mw = 31-50 kDa, 98-99% hydrolysed) and 2% w/w sodium tetraydroxy borate) 4 times per day 10&#xD;
      healthy patients will be selected to participate in the study to test the salivary level of&#xD;
      endocan in the healthy individuals (negative control group)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Actual">May 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain score VAS (Visual Analogue Scale)</measure>
    <time_frame>one week</time_frame>
    <description>The patients will be asked to record the daily level of pain severity of the ulcers through VAS (Visual Analogue Scale). It consisted of a 10-cm horizontal line, and the end of the line is (0) indicating &quot;no pain&quot; and the other end is (10) denoting &quot;unbearable pain&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>healing duration</measure>
    <time_frame>one week</time_frame>
    <description>patient evaluated by how long the ulcer takes to heal from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>size of the ulcer</measure>
    <time_frame>one week</time_frame>
    <description>measuring the ulcer size at baseline,5 days, and one week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>salivary endocan level</measure>
    <time_frame>one week</time_frame>
    <description>enzyme-linked immunosorbent assays to measure the salivary concentrations of endocan marker at the first visit (i.e., before treatment) and the other was just after healing</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Oral Ulcer</condition>
  <arm_group>
    <arm_group_label>basil extract mucoadhesive gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients treated with mucoadhesive gel containing 2% of basil extract 4 times per day (test group) for 20 min after every meal and before going to bed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mucoadhesive placebo gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 patients treated by mucoadhesive gel without drug which was used as placebo (contains tragacanth gum, alcohol, sodium benzoate, and distilled water) 4 times per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy patients</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>10 healthy patients will be selected to participate in the study to test the salivary level of endocan in the healthy individuals (negative control group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>use of basil extract gel in treatment of aphthus ulcer</intervention_name>
    <description>This study aimed to evaluate the efficacy of basil extract (Ocimum basilicum) in the treatment of aphthous ulcers</description>
    <arm_group_label>basil extract mucoadhesive gel</arm_group_label>
    <other_name>anti inflammatory and immunomodulation effect of basil extract</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>muco adhesive placebo gel</intervention_name>
    <description>mucoadhesive gel without drug which was used as placebo (contains tragacanth gum, alcohol, sodium benzoate, and distilled water) 4 times per day</description>
    <arm_group_label>mucoadhesive placebo gel</arm_group_label>
    <other_name>placebo gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no treatment</intervention_name>
    <description>(i) had underlying systemic disease(s) or a history of immunologic disorder(s); (ii) were taking immunomodulatory agents or systemic nonsteroidal anti-inflammatory drugs &lt; 1 month before study commencement; (iii) are smokers; (iv) are pregnant; (v) had a history of abusing drugs or alcohol; (vi) could not provide written informed consent.</description>
    <arm_group_label>healthy patients</arm_group_label>
    <other_name>negative control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt; 18 years;&#xD;
&#xD;
          -  a clear history of RAS (recurrent apthous stomatitis) occurring no less than four&#xD;
             times a year;&#xD;
&#xD;
          -  presentation with one or two ulcers measuring 10 mm in diameter for 48 hours and yet&#xD;
             to receive treatment;&#xD;
&#xD;
          -  ulcers that took &gt; 5 days to resolve without treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  had underlying systemic disease(s) or a history of immunologic disorder(s);&#xD;
&#xD;
          -  were taking immunomodulatory agents or systemic nonsteroidal anti-inflammatory drugs &lt;&#xD;
             1 month before study commencement;&#xD;
&#xD;
          -  are smokers;&#xD;
&#xD;
          -  are pregnant;&#xD;
&#xD;
          -  had a history of abusing drugs or alcohol;&#xD;
&#xD;
          -  could not provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>malak YM shoukheba</last_name>
    <role>Principal Investigator</role>
    <affiliation>faculty of dentistry tanta university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>malak m shoukheba</last_name>
    <phone>+201012663927</phone>
    <email>smalakyousefmohamed@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>malak m shoukheba</last_name>
    <phone>+20403335631</phone>
    <email>smalakyousefmohamed@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Malak Yousef Mohamed Shoukheba</name>
      <address>
        <city>Tanta</city>
        <zip>20</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>malak YM shoukheba</last_name>
      <email>smalakyousefmohamed@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>malak mohamed shoukheba</investigator_full_name>
    <investigator_title>associate prof.</investigator_title>
  </responsible_party>
  <keyword>Aphthous Stomatitis</keyword>
  <keyword>basil extract</keyword>
  <keyword>endocan marker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Stomatitis, Aphthous</mesh_term>
    <mesh_term>Oral Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

